Top

Quality of Life Research

Gepubliceerd in:

26-09-2016

Assessment of health-related quality of life, mental health status and psychological distress based on the type of pharmacotherapy used among patients with depression

Auteurs: Drishti Shah, Varun Vaidya, Amit Patel, Mary Borovicka, Monica-Holiday Goodman

Gepubliceerd in: Quality of Life Research | Uitgave 4/2017

Abstract

Purpose

Effectiveness of antidepressants is generally comparable between and within classes. However, real-world studies on antidepressant treatment and its consequences on the overall quality of life and mental health of individuals are limited. The purpose of this study was to examine the association of specific class of antidepressants with the health-related quality of life, psychological distress and self-reported mental health of individuals suffering from depression who are on monotherapy.

Methods

This retrospective, longitudinal study included individuals with depression who were on antidepressant monotherapy, using data from 2008 to 2011 Medical Expenditure Panel Survey (MEPS). Changes in health-related quality of life, self-reported mental health and psychological distress over a year’s time were observed. A multinomial logistic regression model was built to examine the association between the class of antidepressant medications and the dependent variables.

Results

A total of 688 adults met the study inclusion criteria. No significant difference was observed in the change in Physical Component Summary (PCS), self-reported mental health and psychological distress based on the class of antidepressants. However, individuals on serotonin–norepinephrine reuptake inhibitors (SNRIs) (OR 0.337, 95 % CI 0.155–0.730) were significantly less likely to show improvement on Mental Component Summary (MCS) scores as compared to those on selective serotonin reuptake inhibitors (SSRIs).

Conclusions

The study findings suggest that practitioners should be aware of the differences in the health-related quality of life of those taking SSRIs versus other classes of antidepressants. Further research needs to be done to determine the reason for SSRIs to show greater improvement on mental health as compared to SNRIs.

vorige artikel Dating violence, quality of life and mental health in sexual minority populations: a path analysis

volgende artikel Change in physical function among women as they age: findings from the Australian Longitudinal Study on Women’s Health

Centers for Disease Control and Prevention. (2011). An estimated 1 in 10 U.S. adults report depression. Retrieved August 22, 2011 from http://www.cdc.gov/Features/dsDepression.

Wells, K. B., Stewart, A., Hays, R. D., et al. (1989). The functioning and well-being of depressed patients: results from the Medical Outcomes Study. Journal of the American Medical Association, 262, 916–919.

Broadhead, E. W., Blazer, D. G., George, L. K., et al. (1990). Depression, disability days and days lost from work in a prospective epidemiologic survey. Journal of the American Medical Association, 264, 2524–2528.CrossRefPubMed

Ormel, J., VonKorff, M., Ustun, B., et al. (1994). Common mentadisorders and disability across cultures: results from the WHO collaborative study on psychological problems in general health care. Journal of the American Medical Association, 272, 1741–1748.CrossRefPubMed

Cramer, J. A., & Rosenheck, R. (1998). Compliance with medication regimens for mental and physical disorders. Psychiatric Services, 49(2), 196–201.CrossRefPubMed

National Center for Health Statistics. Health, U. S. (2010). With, & special feature on death and dying. Table 95. Hyattsville, M. http://www.cdc.gov/nchs/data/hus/hus10.pdf.

Centres for Medicare and Medicaid & Medicaid Services. (2013). Antidepressant medications: Use in adults, from http://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/Downloads/ad-adult-factsheet.pdf.

American Psychiatric Association. (2010). Practice guideline for the treatment of patients with major depressive disorder. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf.

Stark, P., & Hardison, C. D. (1985). A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depressive disorder. Journal of Clinical Psychiatry, 46(3 (Sect. 2)), 53–58.PubMed

10.

Song, F., Freemantle, N., Sheldon, T., et al. (1993). Selective serotonin reuptake inhibitors: Meta-analysis of efficacy and acceptability. British Medical Journal, 306, 683–687.CrossRefPubMedPubMedCentral

11.

Workman, E., & Short, D. (1993). Atypical antidepressants versus imipramine in the treatment of major depression. Journal of Clinical Psychiatry, 54, 5–12.PubMed

12.

Rickels, S., Schweizer, E., Clary, C., et al. (1994). Nefazodone and imipramine in major depression: A placebo-controlled trial. British Journal of Psychiatry, 164, 802–805.CrossRefPubMed

13.

Mendels, J., Reimherr, F., Marcus, R. N., et al. (1995). A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients. Journal of Clinical Psychiatry, 56(6 Suppl.), 30–36.PubMed

14.

Preskorn, S. H. (1995). Comparison of the tolerability of bupropion fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. Journal of Clinical Psychiatry, 56(Suppl.), 12–21.PubMed

15.

Simon, G. E., VonKorff, M., Heiligenstein, J. H., et al. (1996). Initial antidepressant choice in primary care: Effectiveness and cost of fluoxetine vs tricyclic antidepressants. Journal of the American Medical Association, 275, 1897–1902.CrossRefPubMed

16.

IsHak, W. W., Greenberg, J. M., Balayan, K., Kapitanski, N., Jeffrey, J., Fathy, H., et al. (2011). Quality of life: The ultimate outcome measure of interventions in major depressive disorder. Harvard Review of Psychiatry, 19(5), 229–239.CrossRefPubMed

17.

Bolton, J. M., & Robinson, J. (2010). Population-attributable fractions of Axis I and Axis II mental disorders for suicide attempts: Findings from a representative sample of the adult, noninstitutionalized US population. American Journal of Public Health, 100(12), 2473–2480.CrossRefPubMedPubMedCentral

18.

Lorenz, R. A., Whitley, H. P., & McCoy, E. K. (2010). Safety of varenicline in patients with mental illness. Primary Psychiatry, 17(9), 60–66.

19.

AHRQ. (2011). MEPS-HC sample design and collection process. Rockville: AHRQ. [cited 2011 17th February]. http://www.meps.ahrq.gov/mepsweb/survey_comp/hc_data_collection.jsp.

20.

AHRQ. (2008). MEPS HC-120: 2008 Medical Conditions. Center for Financing, Access, and Cost Trends540. Gaither Road Rockville, MD: Agency for Healthcare Research and Quality; 2010. cited 2012 9th August]. http://meps.ahrq.gov/mepsweb/data_stats/download_data/pufs/h120/h120doc.shtml.

21.

Khanna, R., Bhanegaonkar, A., Colsher, P., Madhavan, S. S., & Halverson, J. (2009). Breast cancer screening, incidence, and mortality in West Virginia. West Virginia Medical Journal, 105(S1), 24–32.PubMed

22.

Cheak-Zamora, N., Wyrwich, K., & McBride, T. (2009). Reliability and validity of the SF-12v2 in the medical expenditure panel survey. Quality of Life Research, 18(6), 727–735. doi:10.1007/s11136-009-9483-1.CrossRefPubMed

23.

Ware, J. E. J., Kosinski, M., & Keller, S. D. (1996). A 12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity. Medical Care, 34(3), 220–233.CrossRefPubMed

24.

Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003). Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Medical Care, 41, 582–592.PubMed

25.

Kessler, R. C., Andrews, G., Colpe, L. J., Hiripi, E., Mroczek, D. K., Normand, S.-L. T., et al. (2002). Short screening scales to monitor population prevalences and trends in nonspecific psychological distress. Psychological Medicine, 32(6), 959–976.CrossRefPubMed

26.

Hoff, R. A., Bruce, M. L., Kasl, S. V., et al. (1997). Subjective ratings of emotional health as a risk factor for major depression in a community sample. The British Journal of Psychiatry, 170, 167–172.CrossRefPubMed

27.

Al-Ruthia, Y. S., Hong, S. H., & Solomon, D. (2015). Do depressed patients on adjunctive atypical antipsychotics demonstrate a better quality of life compared to those on antidepressants only? A comparative cross-sectional study of a nationally representative sample of the US population. Research in Social and Administrative Pharmacy, 11(2), 228–240.CrossRefPubMed

28.

Selective serotonin and norepinephrine reuptake inhibitors (SNRI) for patients with depression: Executive summary of final report A05-20A, Version 1.0 (2005). In Institute for Quality and Efficiency in Health Care: Executive Summaries. Cologne, Germany: IQWiG (Institute for Quality and Efficiency in Health Care). https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0049661.

29.

Taylor, D., Paton, C., & Kapur, S. (2012). The South London and Maudsley NHS FoundationTrust Prescribing Guidelines in Psychiatry (11th ed.). London: Wiley.

30.

Maity, N., Ghosal, M. K., Gupta, A., Sil, A., Chakraborty, S., & Chatterjee, S. (2014). Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: A randomized, open-label controlled trial. Indian Journal of Pharmacology, 46(4), 433–437. doi:10.4103/0253-7613.135959.CrossRefPubMedPubMedCentral

31.

Nordstrom, G., Danchenko, N., Despiegel, N., & Marteau, F. (2012). Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder. Value Health, 15(2), 231–239. doi:10.1016/j.jval.2011.09.011.CrossRefPubMed

32.

Kornstein, S. G., Li, D., Mao, Y., Larsson, S., Andersen, H. F., & Papakostas, G. I. (2009). Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: Integrative analysis of four double-blind, randomized clinical trials. CNS Spectrums, 14(06), 326–333.CrossRefPubMed

33.

Bauer, M., Tharmanathan, P., Volz, H. P., Moeller, H. J., & Freemantle, N. (2009). The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: A meta-analysis. European Archives of Psychiatry and Clinical Neuroscience, 259, 172–185.CrossRefPubMed

34.

Cipriani, A., Brambilla, P., Furukawa, T. A., Geddes, J., Gregis, M., & Hotopf, M., et al. (2005). Fluoxetine versus other types of pharmacotherapy for depression. The Cochrane Database of Systematic Reviews, (4), CD004185–CD004185. doi:10.1002/14651858.CD004185.pub2.

35.

Panzer, M. J. (2005). Are SSRIs really more effective for anxious depression? Annals of Clinical Psychiatry, 17, 23–29.CrossRefPubMed

36.

Fleishman, J. A., & Zuvekas, S. H. (2007). Global self-rated mental health: associations with other mental health measures and with role functioning. Medical Care, 45(7), 602–609.CrossRefPubMed

37.

Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., & Gaynes, B. N. (2010). Health-related quality of life in depression: A STAR* D report. Annals of Clinical Psychiatry, 22(1), 43–55.PubMed

38.

Steger, M. F., & Kashdan, T. B. (2009). Depression and everyday social activity, belonging, and well-being. Journal of Counseling Psychology, 56(2), 289–300. doi:10.1037/a0015416.CrossRefPubMedPubMedCentral

Titel: Assessment of health-related quality of life, mental health status and psychological distress based on the type of pharmacotherapy used among patients with depression
Auteurs: Drishti Shah
Varun Vaidya
Amit Patel
Mary Borovicka
Monica-Holiday Goodman
Publicatiedatum: 26-09-2016
Uitgeverij: Springer International Publishing
Gepubliceerd in: Quality of Life Research / Uitgave 4/2017
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-016-1417-0

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Purpose

Methods

Results

Conclusions

Log in om toegang te krijgen

Andere artikelen Uitgave 4/2017

Mental health and health-related quality of life of Chinese college students who were the victims of dating violence

Impact of neurocognitive deficits on patient–proxy agreement regarding health-related quality of life in low-grade glioma patients

The importance of considering differential item functioning in investigating the impact of chronic conditions on health-related quality of life in a multi-ethnic Asian population

Change in physical function among women as they age: findings from the Australian Longitudinal Study on Women’s Health

“Life is at a standstill” Quality of life after lower extremity trauma in Malawi

Validation of the Patient Activation Measure (PAM-13) among adults with cardiac conditions in Singapore